Zac Coughlin, Chief Financial Officer, said, “We drove solid first quarter results, which included low-single digit revenue growth and non-GAAP earnings per share above our guidance. We are navigating a highly dynamic and uncertain macroeconomic environment that is impacting our industry, our consumers, and our business results. We are reaffirming our revenue guidance for the
Instil Bio Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS,
_____________________1Non-GAAP financial measure; please see supplemental reconciliations of GAAP to non-GAAP financial measures at the end of this release. The impairment was the result of the full cost ceiling limitation, driven in part by the decline in the trailing 12-month oil price calculation, and excludes the value of $145.9 million for the Company’s commodity derivative
“The first quarter of 2025 showed strong execution of our strategic initiatives and demonstrates that we are steering Stem in the right long-term direction,” said Doran Hole, Chief Financial Officer and Executive Vice President of Stem. “We achieved strong GAAP and non-GAAP gross margins, driven by the strength of our high-margin software, services, and edge
Recent Business Highlights: Signed a Record Total Contract Value Deal: This multi-million dollar contract over a multi-year period speaks to our customer value proposition and our continued success moving upmarket. Unveiled B2 Cloud Storage Overdrive: New offering provides high performance throughput at great value, optimized for data-intensive workloads such as training AI models. Deepened Strategic
Key financial results for the fiscal second quarter are shown in the table below. GAAP Non-GAAP Q2’25 Q2’24 Change Increase (Decrease) Q2’25 Q2’24 Change Increase (Decrease) Revenue $1,005.3 $1,017.8 (1.2%) $1,005.3 $1,017.8 (1.2%) Gross margin 37.5% 53.3% (1,580 bps) 61.1% 60.7% 40 bps Operating expenses $384.3 $331.9 15.8%
Financial Outlook We are providing estimates for the second quarter and full year 2025 based on current market conditions and expectations. The revenue growth rates are adjusted for constant currency to provide better visibility into the underlying business trends. We emphasize that these estimates are subject to various important cautionary factors referenced in the section
HUNTSVILLE, Ala., February 27, 2025–(BUSINESS WIRE)–ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) (“ADTRAN Holdings” or the “Company”) today announced its preliminary unaudited financial results for the fourth quarter and full-year ended December 31, 2024. Adtran Holdings’ Chairman and Chief Executive Officer Tom Stanton stated, “Market conditions continued to improve during the fourth quarter driven
MILPITAS, Calif., February 19, 2025–(BUSINESS WIRE)–SolarEdge Technologies, Inc. (Nasdaq: SEDG), a global leader in smart energy technology, today announced its financial results for the fourth quarter ended December 31, 2024 and full year ended December 31, 2024. “There are exciting opportunities ahead for SolarEdge,” said Shuki Nir, CEO of SolarEdge. “We are just getting started